Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Stress, Depression and Antidepressant Treatment Options in Patients Suffering from Multiple Sclerosis.
A Clinical Study Using MEDI-551 in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies
Active Biotech's partner Teva initiates a laquinimod clinical trial in Huntington's disease
Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study.
Immunosuppressive monoclonal antibodies: current and next generation.
A validated regulatory network for Th17 cell specification.
Aggressive multiple sclerosis: proposed definition and treatment algorithm.
Multiple sclerosis susceptibility loci do not alter clinical and MRI outcomes in clinically isolated syndrome.
Hope for a rare disease: eculizumab in neuromyelitis optica.
Network-Based Multiple Sclerosis Pathway Analysis with GWAS Data from 15,000 Cases and 30,000 Controls.
The effects of robot-assisted gait training in progressive multiple sclerosis: A randomized controlled trial.
Recommendations for the detection and therapeutic management of cognitive impairment in multiple sclerosis.
[Treatment of nausea and vomiting with 5HT3 receptor antagonists, steroids, antihistamines, anticholinergics, somatostatinantagonists, benzodiazepines and cannabinoids in palliative care patients : A systematic review.]
No association of IFI16 (interferon-inducible protein 16) variants with susceptibility to multiple sclerosis.
Regional but Not Global Brain Damage Contributes to Fatigue in Multiple Sclerosis.
Soluble adenylyl cyclase is necessary and sufficient to overcome the block of axonal growth by myelin-associated factors.
The Opioid System and Brain Development: Effects of Methadone on the Oligodendrocyte Lineage and the Early Stages of Myelination.
Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.
Fingolimod Increases CD39-Expressing Regulatory T Cells in Multiple Sclerosis Patients.
Multiple sclerosis, cannabis, and cognition: A structural MRI study.
VIP Deficient Mice Exhibit Resistance to Lipopolysaccharide Induced Endotoxemia with an Intrinsic Defect in Proinflammatory Cellular Responses.
Alcohol as a Modifiable Lifestyle Factor Affecting Multiple Sclerosis Risk.
Hearing statement in multiple sclerosis: a case control study using auditory brainstem responses and otoacoustic emissions.
A new computerised cognitive test for the detection of information processing speed impairment in multiple sclerosis.
Neuroprotection With Phenytoin in Optic Neuritis
Pages
« first
‹ previous
…
199
200
201
202
203
204
205
206
207
…
next ›
last »